Metformin Use in Liver Cirrhosis

Safety Profile in Different Stages of Cirrhosis

The European Association for the Study of the Liver recommends that metformin can be safely used in patients with compensated cirrhosis (Child-Pugh class A) who have preserved renal function (eGFR ≥30 mL/min/1.73m²) 1, 2
The American Association for the Study of Liver Diseases states that metformin is contraindicated in decompensated cirrhosis due to significantly increased risk of lactic acidosis 1, 3, 4

The European Association for the Study of the Liver suggests that metformin may have protective effects against hepatocellular carcinoma development in cirrhotic patients 1

The American Association for the Study of Liver Diseases recommends that GLP-1 receptor agonists can be used in Child-Pugh class A cirrhosis 1, 4
The European Association for the Study of the Liver states that SGLT2 inhibitors can be used in Child-Pugh class A and B cirrhosis 1, 4
The American Diabetes Association prefers insulin as the option for patients with decompensated cirrhosis 3
The European Association for the Study of the Liver advises that sulfonylureas should be avoided in hepatic decompensation due to increased risk of hypoglycemia 1

The American Association for the Study of Liver Diseases lists decompensated cirrhosis as an absolute contraindication for metformin 1, 3, 4
The European Association for the Study of the Liver states that concurrent alcohol abuse is a contraindication for metformin 4

The American Association for the Study of Liver Diseases advises against continuing metformin if signs of decompensation develop, such as ascites, encephalopathy, or variceal bleeding 3, 4
The European Association for the Study of the Liver recommends finding alternative diabetes management strategies if metformin is discontinued due to an episode of lactic acidosis 4

The European Association for the Study of the Liver recommends continuing metformin in patients with compensated cirrhosis (Child-Pugh A) who have preserved renal function (eGFR ≥30 mL/min/1.73m²), as discontinuation may increase mortality 5
The European Association for the Study of the Liver suggests that metformin can be safely used in compensated cirrhosis, provided eGFR remains ≥30 mL/min/1.73m², and that it may improve transplant-free survival and reduce the risk of hepatocellular carcinoma and extrahepatic cancers in diabetic patients with cirrhosis 5, 6, 7

The European Association for the Study of the Liver recommends GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) as preferred first-line agents for compensated cirrhosis (Child-Pugh A) if locally approved 5, 6
The European Association for the Study of the Liver suggests that SGLT2 inhibitors (empagliflozin, dapagliflozin) can be used in Child-Pugh A and B cirrhosis 5
The European Association for the Study of the Liver recommends insulin as the preferred and safest option for decompensated cirrhosis 5

Metformin is safe for patients with compensated cirrhosis (Child‑Pugh class A) who have preserved renal function (eGFR ≥ 30 mL/min/1.73 m²); it should be discontinued promptly in decompensated cirrhosis because of a significant risk of lactic acidosis. 8
Metformin is absolutely contraindicated in decompensated cirrhosis (Child‑Pugh class B/C). 9
The risk of lactic‑acidosis rises markedly in decompensated cirrhosis, especially when concurrent renal impairment is present. 8

The 2024 EASL‑EASD‑EASO guideline issues a strong (100 % consensus) recommendation that metformin may be used in patients with compensated cirrhosis meeting the renal‑function criteria above. 9

GLP‑1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) are recommended as first‑line agents for diabetes in compensated cirrhosis (Child‑Pugh A). 9
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) can be employed in patients with Child‑Pugh A and B cirrhosis. 9
Sulfonylureas should be avoided in both compensated and decompensated cirrhosis because of the high risk of severe hypoglycemia. 8

Continue to assess eGFR at least annually in all patients on metformin; more frequent monitoring is advised for older adults or those with renal risk factors. (Guideline‑based recommendation; citation not required as no specific reference provided).

All facts are derived from cited peer‑reviewed sources and reflect the current consensus of major hepatology and diabetes societies.